Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VSTM1 (SIRL-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VSTM1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View VSTM1 Products |
| Gene Delivery | VSTM1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines (including myeloid lineage). |
View VSTM1 Products |
| Benchmark Ab | Anti-VSTM1 Recombinant Antibody Sequence-defined positive control for binding and blockade assays. |
View VSTM1 Products |
| Validator | VSTM1 siRNA Set For knockdown verification and specificity controls. |
View VSTM1 Products |
| Related Target A | S100A8 Potential endogenous ligand; crucial for binding inhibition assays. |
View S100A8 Products |
| Related Target B | TREM2 Synergistic myeloid checkpoint target in neuroinflammation and tumor microenvironment. |
View TREM2 Products |
| Related Target C | VSIR (VISTA) Parallel myeloid checkpoint; combination rationale for dual targeting. |
View VSIR Products |
| Related Target D | CD47 Myeloid innate immune axis; complementary tumor microenvironment modulation. |
View CD47 Products |
| Related Target E | ITGAM (CD11b) / ITGB2 (CD18) Potential interaction partner for integrin-binding validation. |
View ITGAM Products / View ITGB2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation for Ligand Binding | HEK293 Expressed ECD-Fc ensures intact post-translational modifications necessary for potential S100/AMP interactions. |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity for cross-reactivity SPR/BLI screening. |
| Lack of Controls | Recombinant positive control antibodies included for robust baseline establishment. |
| False Positives in Cell Assays | Validated siRNA included for precise specificity and knockdown verification. |
| V-set Ig Superfamily Counter-screening | Homolog panel proteins (VSIR, CD47, SIRPA) available for off-target assessment. |
| Integrin Heterodimer Binding Validation | Human ITGAM/ITGB2 co-expression proteins available with >95% purity for complex formation assays. |
Live VSTM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VSTM1 (Signal inhibitory receptor on leukocytes-1) therapeutics is expanding as its role as an innate immune checkpoint becomes clearer. Expressed primarily on monocytes, macrophages, and granulocytes, VSTM1 inhibits the oxidative burst and inflammatory cytokine release upon binding to endogenous danger signals like S100 proteins and antimicrobial peptides (e.g., LL-37). Major players are currently exploring Agonistic Monoclonal Antibodies to suppress excessive inflammation in autoimmune conditions such as systemic lupus erythematosus (SLE) and COPD. Conversely, the future trend highlights Antagonistic Modalities in the oncology space, designed to relieve myeloid-derived suppression in the tumor microenvironment, functioning synergistically with T-cell checkpoints. As the field pivots toward tumor-associated macrophage (TAM) reprogramming strategies, VSTM1 offers a novel entry point for myeloid-selective immunotherapies with reduced on-target off-tumor liability compared to pan-immune checkpoints.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | Early-stage Biotechs, Academic Spin-offs | Autoimmune Diseases (SLE, RA, COPD) | Receptor Activation Assay (Need high-purity HEK293 expressed ECD-Fc for structure preservation) |
| Antagonist mAb | Immuno-Oncology Innovators, Academic Consortia | Solid Tumors (Myeloid Suppression) | Ligand Blocking Assay (Need high-purity ECD-Fc for ligand competition) |
| Bispecifics / ADC | Preclinical Pipelines, Emerging Platforms | Hematologic Malignancies, Tumor Microenvironment | Heterodimer Validation / Internalization Assay (Need cross-reactive ortholog proteins, lentivirus cell lines) |
| Small Molecule / Peptide | Discovery-stage Programs | Autoimmune Disease | Selectivity Assay (Need VSTM1 vs VISTA panel proteins) |
Key Functional Domains & Mutations
- Ig-like V-type domain: Confirmed by UniProt Q6UX27, critical for ligand recognition and signaling.
- Key Mutation: dbSNP rs2433724 (UniProt VAR_030034), may influence receptor function or expression.
TarMart Reagent Specifications
All VSTM1 proteins are produced in HEK293 mammalian cells with native glycosylation, purity >95%, endotoxin <1EU/µg, and sequence verified by mass spectrometry. Available formats include ECD-Fc, full-length lentivirus, recombinant antibodies, and siRNA sets for comprehensive assay development.